Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
15
×
life sciences
national blog main
boston blog main
boston top stories
fda
national top stories
san francisco top stories
new york top stories
san francisco blog main
boston
drugs
new york blog main
biotech
europe top stories
national
san diego blog main
san diego top stories
alnylam pharmaceuticals
cancer
europe blog main
rna interference
svb leerink
allergan
amgen
aminolevulinic acid
blueprint medicines
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
givosiran
indiana blog main
indiana top stories
marc goodman
new york
onpattro
patisiran
raleigh-durham blog main
raleigh-durham top stories
What
drug
15
×
medicine
15
×
fda
approved
new
data
pharmaceuticals
alnylam
approval
cancer
market
patients
rnai
second
seek
ago
announced
filing
interference
making
marketing
medicines
nasdaq
nod
ok
oks
post
rna
specifically
speedy
type
weeks
weight
world
aces
afternoon
aldeyra
alkermes
alnylam’s
amgen
Language
unset
Current search:
medicine
×
drug
×
" clinical trials "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com
5 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority